CNS PHARMACEUTICALS INC (CNSP) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:CNSP • US18978H5081

5.41 USD
-0.17 (-3.05%)
At close: Feb 2, 2026
5.39 USD
-0.02 (-0.37%)
After Hours: 2/2/2026, 8:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CNSP. CNSP was compared to 191 industry peers in the Pharmaceuticals industry. The financial health of CNSP is average, but there are quite some concerns on its profitability. CNSP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • CNSP had negative earnings in the past year.
  • CNSP had a negative operating cash flow in the past year.
  • CNSP had negative earnings in each of the past 5 years.
  • In the past 5 years CNSP always reported negative operating cash flow.
CNSP Yearly Net Income VS EBIT VS OCF VS FCFCNSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -110.13%, CNSP is doing worse than 79.06% of the companies in the same industry.
  • With a Return On Equity value of -131.90%, CNSP is not doing good in the industry: 68.06% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -110.13%
ROE -131.9%
ROIC N/A
ROA(3y)-465.36%
ROA(5y)-324.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNSP Yearly ROA, ROE, ROICCNSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

  • CNSP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNSP Yearly Profit, Operating, Gross MarginsCNSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

  • CNSP has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CNSP has more shares outstanding
  • Compared to 1 year ago, CNSP has an improved debt to assets ratio.
CNSP Yearly Shares OutstandingCNSP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K 100K
CNSP Yearly Total Debt VS Total AssetsCNSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • CNSP has an Altman-Z score of -12.81. This is a bad value and indicates that CNSP is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -12.81, CNSP is doing worse than 76.96% of the companies in the same industry.
  • CNSP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.00, CNSP is doing good in the industry, outperforming 60.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.81
ROIC/WACCN/A
WACCN/A
CNSP Yearly LT Debt VS Equity VS FCFCNSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

  • A Current Ratio of 5.81 indicates that CNSP has no problem at all paying its short term obligations.
  • CNSP's Current ratio of 5.81 is fine compared to the rest of the industry. CNSP outperforms 67.54% of its industry peers.
  • CNSP has a Quick Ratio of 5.81. This indicates that CNSP is financially healthy and has no problem in meeting its short term obligations.
  • CNSP has a better Quick ratio (5.81) than 68.59% of its industry peers.
Industry RankSector Rank
Current Ratio 5.81
Quick Ratio 5.81
CNSP Yearly Current Assets VS Current LiabilitesCNSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 99.73% over the past year.
EPS 1Y (TTM)99.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 18.13% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.15%
EPS Next 2Y40.94%
EPS Next 3Y25.71%
EPS Next 5Y18.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNSP Yearly Revenue VS EstimatesCNSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 50M 100M 150M 200M
CNSP Yearly EPS VS EstimatesCNSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -100K -200K -300K -400K -500K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • CNSP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CNSP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNSP Price Earnings VS Forward Price EarningsCNSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNSP Per share dataCNSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CNSP's earnings are expected to grow with 25.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.94%
EPS Next 3Y25.71%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for CNSP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CNS PHARMACEUTICALS INC

NASDAQ:CNSP (2/2/2026, 8:00:00 PM)

After market: 5.39 -0.02 (-0.37%)

5.41

-0.17 (-3.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners9.16%
Inst Owner Change-40.13%
Ins Owners0%
Ins Owner Change0%
Market Cap3.35M
Revenue(TTM)N/A
Net Income(TTM)-13.07M
Analysts82.5
Price Target53.04 (880.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.42%
Min EPS beat(2)20.41%
Max EPS beat(2)34.44%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)11.09%
EPS NQ rev (3m)22.35%
EPS NY rev (1m)13.51%
EPS NY rev (3m)18.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.34
EV/EBITDA N/A
EPS(TTM)-130.83
EYN/A
EPS(NY)-6.46
Fwd EYN/A
FCF(TTM)-26.18
FCFYN/A
OCF(TTM)-26.18
OCFYN/A
SpS0
BVpS15.98
TBVpS15.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -110.13%
ROE -131.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-465.36%
ROA(5y)-324.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.81
Quick Ratio 5.81
Altman-Z -12.81
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)74.13%
Cap/Depr(5y)104.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.16%
EPS Next Y94.15%
EPS Next 2Y40.94%
EPS Next 3Y25.71%
EPS Next 5Y18.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.65%
OCF growth 3YN/A
OCF growth 5YN/A

CNS PHARMACEUTICALS INC / CNSP FAQ

What is the fundamental rating for CNSP stock?

ChartMill assigns a fundamental rating of 2 / 10 to CNSP.


What is the valuation status for CNSP stock?

ChartMill assigns a valuation rating of 1 / 10 to CNS PHARMACEUTICALS INC (CNSP). This can be considered as Overvalued.


How profitable is CNS PHARMACEUTICALS INC (CNSP) stock?

CNS PHARMACEUTICALS INC (CNSP) has a profitability rating of 0 / 10.


How financially healthy is CNS PHARMACEUTICALS INC?

The financial health rating of CNS PHARMACEUTICALS INC (CNSP) is 4 / 10.